Pathstone Family Office’s 10x Genomics TXG Stock Holding History

Pathstone Family Office’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,912	Closed	-$219K	–	1692
2023 Q2	$219K	Sell	3,912 -461	-11%	-$25K	﹤0.01%	1107
2023 Q1	$244K	Sell	4,373 -5,039	-54%	-$235K	﹤0.01%	1005
2022 Q4	$526K	Buy	+9,412	New	+$308K	﹤0.01%	1071
2022 Q1	–	Sell	-1,931	Closed	-$288K	–	1034
2021 Q4	$288K	Buy	1,931 +113	+6%	+$17.3K	0.01%	725
2021 Q3	$264K	Buy	1,818 +663	+57%	+$114K	0.01%	718
2021 Q2	$226K	Buy	+1,155	New	+$209K	0.01%	735
2021 Q1	–	Sell	-70	Closed	-$10K	–	1299
2020 Q4	$10K	Sell	70 -70	-50%	-$10.2K	﹤0.01%	881
2020 Q3	$17K	Buy	+140	New	+$14.7K	﹤0.01%	512

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Pathstone Family Office's TXG Position: Q3 2023 in Review

Pathstone Family Office sold out of 10x Genomics (TXG) in Q3 2023, closing a stake of 3,912 shares — an estimated $219K sold.

Pathstone Family Office first reported a position in TXG in Q3 2020 and held it in 8 quarters. The position peaked at $526K in Q4 2022. 256 funds tracked by Wall St. Rank hold TXG as of Q3 2023.

Pathstone Family Office reported no remaining 10x Genomics position as of Q3 2023 after selling out during the quarter.
Pathstone Family Office sold 3,912 10x Genomics shares in Q3 2023, an estimated $219K.
Pathstone Family Office first reported a position in 10x Genomics in Q3 2020 and held it in 8 quarters.
Pathstone Family Office's 10x Genomics position peaked at $526K in Q4 2022.
256 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.